MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517067567 A) filed by Eli Lilly And Company, Indianapolis, on July 15, for 'novel rna therapeutics and uses thereof.'
Inventor(s) include Antonellis, Patrick Joseph; Beyer, Thomas Patrick; Branttie, Jean Mawuena; Cheng, Christine Chih-Tao; Debets, Marjoke F.; Gavardinas, Konstantinos; Lackner, Gregory Lawrence; Wang, Jibo; and Wilson, Takako.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia)."
The patent application was internationally filed on Dec. 22, 2023, under International application No.PCT/US2023/085630.
Disclaimer: Curated by HT Syndication.
